 Home > Active Ingredient News > Immunology News > J Am Acad Dermatol: Study on the efficacy and safety of cathepsin S inhibitors in patients with moderate and severe psoriasis

J Am Acad Dermatol: Study on the efficacy and safety of cathepsin S inhibitors in patients with moderate and severe psoriasis

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

seroquel 150 mg

mg sales

pantoprazole 80 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Approximately 20% of patients with psoriasis are moderate to severe and require systemic treatment with cytokine-targeted biological agents
.

However, some patients either have no effect or develop anti-drug antibodies, which reduces the therapeutic effect

Cathepsin S is a cysteine protease that can activate the pro-inflammatory cytokine interleukin (IL)-36γ and play a pathogenic role in psoriasis
.

RO5459072 is a selective, effective cathepsin S inhibitors for the treatment of psoriasis, including itself includes immune diseases developed

immunity

The median treatment time was 67 days
.

After 12 weeks of treatment, the average steady-state blood concentration (±SD) of RO5459072 was 1290 (±614) ng/mL

Infect

We believe that RO5459072 has no therapeutic effect in this trial, which indicates that there is redundancy in the IL-36-dependent pro-inflammatory pathway in psoriasis
.

Cathepsin S activity is significantly up-regulated in psoriatic skin

In conclusion, targeting cathepsin S-mediated IL-36 activation with a highly effective and selective cathepsin S antagonist has no therapeutic effect on psoriasis
.

The mechanism of action of RO5459072 may be too specific, allowing other proteases and/or cytokines to drive the psoriasis phenotype

Literature source: Gadola SD, Färber P, Posch MG, An open-label Phase 2A study investigating the efficacy and safety of a cathepsin S inhibitor in patients with moderate to severe psoriasis, J Am Acad Dermatol 2021 Dec 11;

Gadola SD, Färber P, Posch MG, An open-label Phase 2A study investigating the efficacy and safety of a cathepsin S inhibitor in patients with moderate to severe psoriasis, J Am Acad Dermatol 2021 Dec 11;

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.